β-烟酰胺单核苷酸对生理机能的影响研究进展

摘要/Abstract

摘要： 我国处于亚健康状态的超重或肥胖人群与老龄化人口都在逐年上升，在衰老和肥胖过程中，烟酰胺腺嘌呤二核苷酸（Nicotinamide Adenine Dinucleotide，NAD+）水平会发生系统性下降。NAD+是细胞能量代谢，调节细胞机能，影响衰老的关键靶点，因此通过补充NAD前体以改善生理机能，延缓衰老已经成为目前研究热点。β-烟酰胺单核苷酸（Nicotinamide mononucleotide，NMN）是动物体内内NAD+代谢的中间产物，也是目前最直接高效的NAD+补充前体。但是NMN对生理机能存在多方面多器官的复杂影响，而且人体试验与动物试验结果并不一致，服用量也尚未确定。本文综述NMN到目前为止的动物，人体试验结果，旨在探究补充NMN对动物、人体生理机能的影响，机制，剂量，不良反应，为未来NMN研究与应用提供思路。

关键词: β-烟酰胺单核苷酸（NMN）, 烟酰胺腺嘌呤二核苷酸（NAD）代谢, 动物实验, 人体临床试验, 生理机能

Abstract: The overweight or obese population in sub-health status and the aging population in China are increasing year by year. The cellular level of nicotinamide adenine dinucleotide (NAD+) decreases dramatically with the process of aging and obesity. NAD+ is the key target of cellular energy metabolism, regulating cell function and delaying senescent process . Therefore, it has become a research highlight to improve physiological function and delay aging by supplementing NAD precursors. β-Nicotinamide mononucleotide (NMN) is an intermediate product of NAD+ metabolism in animals, and it is also the most direct and efficient NAD+ supplement precursor at present. However, NMN has complex effects on different organs in many aspects of physiological function, and the results of animal tests are not consistent with human tests , and the dosage has not been determined. This paper summarizes the recent results of NMN animal and human experiments, aiming to explore the effects, mechanisms, doses and adverse reactions of NMN supplementation on animal and human physiological functions, and provide ideas for future researches and application of NMN.

Key words: β-nicotinamide mononucleotide（NMN）, Nicotinamide adenine dinucleotide（NAD） metabolism, Animal experiments, Human clinical trials, Physiological function

中图分类号:

陈韬. β-烟酰胺单核苷酸对生理机能的影响研究进展 [J]. 食品科学, 0, (): 0-0.

Tao Chen. Advance of the effect of β-nicotinamide single nucleotide on physiological function [J]. FOOD SCIENCE, 0, (): 0-0.

参考文献

[1] ORLANDI I, ALBERGHINA L, VAI M. Nicotinamide, Nicotinamide Riboside and Nicotinic Acid-Emerging Roles in Replicative and Chronological Aging in Yeast [J]. Biomolecules, 2020, 10(4)：
[2] GILMOUR B C, GUDMUNDSRUD R, FRANK J, et al. Targeting NAD(+) in translational research to relieve diseases and conditions of metabolic stress and ageing [J]. Mech Ageing Dev, 2020, 186: 111208.
[3] FANG E F, SCHEIBYE-KNUDSEN M, JAHN H J, et al. A research agenda for aging in China in the 21st century [J]. Ageing Res Rev, 2015, 24(Pt B): 197-205.
[4] HEMMINGSSON E. The unparalleled rise of obesity in China: a call to action [J]. Int J Obes (Lond), 2021, 45(5): 921-2.
[5] KHAIDIZAR F D, BESSHO Y, NAKAHATA Y. Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process [J]. Int J Mol Sci, 2021, 22(7).
[6] SANTOS A L, SINHA S. Obesity and aging: Molecular mechanisms and therapeutic approaches [J]. Ageing Res Rev, 2021, 67: 101268.
[7] OKABE K, YAKU K, TOBE K, et al. Implications of altered NAD metabolism in metabolic disorders [J]. J Biomed Sci, 2019, 26(1): 34.
[8] CANTó C, MENZIES K J, AUWERX J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus [J]. Cell Metab, 2015, 22(1): 31-53.
[9] YOSHINO J, BAUR J A, IMAI S I. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR [J]. Cell Metab, 2018, 27(3): 513-28.
[10] BADAWY A A. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects [J]. Int J Tryptophan Res, 2017, 10: 1178646917691938.
[11] BOGAN K L, BRENNER C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition [J]. Annu Rev Nutr, 2008, 28: 115-30.
[12] FREDERICK D W, LORO E, LIU L, et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle [J]. Cell Metab, 2016, 24(2): 269-82.
[13] REVOLLO J R, GRIMM A A, IMAI S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells [J]. J Biol Chem, 2004, 279(49): 50754-63.
[14] BERGER F, LAU C, DAHLMANN M, et al. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms [J]. J Biol Chem, 2005, 280(43): 36334-41.
[15] SAUVE A A. NAD+ and vitamin B3: from metabolism to therapies [J]. J Pharmacol Exp Ther, 2008, 324(3): 883-93.
[16] QUARONA V, ZACCARELLO G, CHILLEMI A, et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules [J]. Cytometry B Clin Cytom, 2013, 84(4): 207-17.
[17] TRAMMELL S A, SCHMIDT M S, WEIDEMANN B J, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans [J]. Nat Commun, 2016, 7: 12948.
[18] REVOLLO J R, K?RNER A, MILLS K F, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme [J]. Cell Metab, 2007, 6(5): 363-75.
[19] SCHMEISSER K, MANSFELD J, KUHLOW D, et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide [J]. Nat Chem Biol, 2013, 9(11): 693-700.
[20] MUKHERJEE S, CHELLAPPA K, MOFFITT A, et al. Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration [J]. Hepatology, 2017, 65(2): 616-30.
[21] GARTEN A, PETZOLD S, BARNIKOL-OETTLER A, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes [J]. Biochem Biophys Res Commun, 2010, 391(1): 376-81.
[22] KOVER K, TONG P Y, WATKINS D, et al. Expression and regulation of nampt in human islets [J]. PLoS One, 2013, 8(3): e58767.
[23] YOON M J, YOSHIDA M, JOHNSON S, et al. SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice [J]. Cell Metab, 2015, 21(5): 706-17.
[24] HARA N, YAMADA K, SHIBATA T, et al. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma [J]. PLoS One, 2011, 6(8): e22781.
[25] RATAJCZAK J, JOFFRAUD M, TRAMMELL S A, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells [J]. Nat Commun, 2016, 7: 13103.
[26] NIKIFOROV A, D?LLE C, NIERE M, et al. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation [J]. J Biol Chem, 2011, 286(24): 21767-78.
[27] LU S P, LIN S J. Phosphate-responsive signaling pathway is a novel component of NAD+ metabolism in Saccharomyces cerevisiae [J]. J Biol Chem, 2011, 286(16): 14271-81.
[28] GROZIO A, MILLS K F, YOSHINO J, et al. Slc12a8 is a nicotinamide mononucleotide transporter [J]. Nat Metab, 2019, 1(1): 47-57.
[29] YOSHINO J, MILLS K F, YOON M J, et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice [J]. Cell Metab, 2011, 14(4): 528-36.
[30] MILLS K F, YOSHIDA S, STEIN L R, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice [J]. Cell Metab, 2016, 24(6): 795-806.
[31] STROMSDORFER K L, YAMAGUCHI S, YOON M J, et al. NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice [J]. Cell Rep, 2016, 16(7): 1851-60.
[32] MARTIN A S, ABRAHAM D M, HERSHBERGER K A, et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model [J]. JCI Insight, 2017, 2(14).
[33] YAMAMOTO T, BYUN J, ZHAI P, et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion [J]. PLoS One, 2014, 9(6): e98972.
[34] GOMES A P, PRICE N L, LING A J, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging [J]. Cell, 2013, 155(7): 1624-38.
[35] GUAN Y, WANG S R, HUANG X Z, et al. Nicotinamide Mononucleotide, an NAD(+) Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner [J]. J Am Soc Nephrol, 2017, 28(8): 2337-52.
[36] NORTH B J, ROSENBERG M A, JEGANATHAN K B, et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan [J]. Embo j, 2014, 33(13): 1438-53.
[37] BERTOLDO M J, LISTIJONO D R, HO W J, et al. NAD(+) Repletion Rescues Female Fertility during Reproductive Aging [J]. Cell Rep, 2020, 30(6): 1670-81.e7.
[38] LIN J B, KUBOTA S, BAN N, et al. NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice [J]. Cell Rep, 2016, 17(1): 69-85.
[39] DE PICCIOTTO N E, GANO L B, JOHNSON L C, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice [J]. Aging Cell, 2016, 15(3): 522-30.
[40] WANG X, HU X, YANG Y, et al. Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death [J]. Brain Res, 2016, 1643: 1-9.
[41] CATON P W, KIESWICH J, YAQOOB M M, et al. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function [J]. Diabetologia, 2011, 54(12): 3083-92.
[42] UDDIN G M, YOUNGSON N A, SINCLAIR D A, et al. Head to Head Comparison of Short-Term Treatment with the NAD(+) Precursor Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese Female Mice [J]. Front Pharmacol, 2016, 7: 258.
[43] LEE C F, CHAVEZ J D, GARCIA-MENENDEZ L, et al. Normalization of NAD+ Redox Balance as a Therapy for Heart Failure [J]. Circulation, 2016, 134(12): 883-94.
[44] MIAO Y, CUI Z, GAO Q, et al. Nicotinamide Mononucleotide Supplementation Reverses the Declining Quality of Maternally Aged Oocytes [J]. Cell Rep, 2020, 32(5): 107987.
[45] TARANTINI S, VALCARCEL-ARES M N, TOTH P, et al. Nicotinamide mononucleotide (NMN) supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses and improves cognitive function in aged mice [J]. Redox Biol, 2019, 24: 101192.
[46] KISS T, NYúL-TóTH á, BALASUBRAMANIAN P, et al. Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects [J]. Geroscience, 2020, 42(2): 527-46.
[47] CAMACHO-PEREIRA J, TARRAGó M G, CHINI C C S, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism [J]. Cell Metab, 2016, 23(6): 1127-39.
[48] YAO Z, YANG W, GAO Z, et al. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease [J]. Neurosci Lett, 2017, 647: 133-40.
[49] PARK J H, LONG A, OWENS K, et al. Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia [J]. Neurobiol Dis, 2016, 95: 102-10.
[50] WEI C C, KONG Y Y, HUA X, et al. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia [J]. Br J Pharmacol, 2017, 174(21): 3823-36.
[51] STEIN L R, IMAI S. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging [J]. Embo j, 2014, 33(12): 1321-40.
[52] DI STEFANO M, NASCIMENTO-FERREIRA I, ORSOMANDO G, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration [J]. Cell Death Differ, 2015, 22(5): 731-42.
[53] GERDTS J, SUMMERS D W, MILBRANDT J, et al. Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism [J]. Neuron, 2016, 89(3): 449-60.
[54] LI J, BONKOWSKI M S, MONIOT S, et al. A conserved NAD(+) binding pocket that regulates protein-protein interactions during aging [J]. Science, 2017, 355(6331): 1312-7.
[55] YOSHINO M, YOSHINO J, KAYSER B D, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women [J]. Science, 2021, 372(6547): 1224-9.
[56] IRIE J, INAGAKI E, FUJITA M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men [J]. Endocr J, 2020, 67(2): 153-60.
[57] LIAO B, ZHAO Y, WANG D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study [J]. J Int Soc Sports Nutr, 2021, 18(1): 54.
[58] DE GUIA R M, AGERHOLM M, NIELSEN T S, et al. Aerobic and resistance exercise training reverses age-dependent decline in NAD(+) salvage capacity in human skeletal muscle [J]. Physiol Rep, 2019, 7(12): e14139.
[59] BROWN K D, MAQSOOD S, HUANG J Y, et al. Activation of SIRT3 by the NAD? precursor nicotinamide riboside protects from noise-induced hearing loss [J]. Cell Metab, 2014, 20(6): 1059-68.
[60] BAI P, CANTO C, BRUNYáNSZKI A, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure [J]. Cell Metab, 2011, 13(4): 450-60.
[61] BAI P, CANTó C, OUDART H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation [J]. Cell Metab, 2011, 13(4): 461-8.
[62] ZHOU C C, YANG X, HUA X, et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing [J]. Br J Pharmacol, 2016, 173(15): 2352-68.
[63] DOLLERUP O L, CHUBANAVA S, AGERHOLM M, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men [J]. J Physiol, 2020, 598(4): 731-54.
[64] GUJAR A D, LE S, MAO D D, et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma [J]. Proc Natl Acad Sci U S A, 2016, 113(51): E8247-e56.
[65] CHALKIADAKI A, GUARENTE L. The multifaceted functions of sirtuins in cancer [J]. Nat Rev Cancer, 2015, 15(10): 608-24.
[66] ZAPATA-PéREZ R, TAMMARO A, SCHOMAKERS B V, et al. Reduced nicotinamide mononucleotide is a new and potent NAD(+) precursor in mammalian cells and mice [J]. Faseb j, 2021, 35(4): e21456.